Staff Profile

Christine J Harrison PhD FRCPath FMedSci

Professor of Childhood Cancer Cytogenetics

Leukaemia Research Cytogenetics Group

Wolfson Childhood Cancer Research Centre

Northern Institute for Cancer Research,

Level 6, Herschel Building

Newcastle University,

Newcastle upon Tyne

Phone: 0191 208 2237

email: christine.harrison@newcastle.ac.uk

Director, Leukaemia Research Fund Cytogenetics Group

Fellow, Academy of Medical Sciences

Fellow, Royal College of Pathologists

Newcastle University, Vice Chancellor Academic Distinction Award 2017

The remit of my research is to improve outcome for patients with acute leukaemia through genetics in UK treatment trials, by characterisation of existing and discovery of novel genetic changes. I have over 30 years’ experience in planning and leading research activities of national/international repute in the area of cytogenetics/genetics of haematological malignancies. I was responsible for the initiation of a database for the cytogenetics of acute leukaemia in 1988, when the importance of chromosomal abnormalities in risk stratification for treatment was becoming evident. This has now developed into a large-scale collection of cytogenetic and genetic data, containing information on more than 28,000 UK patients, which is renowned to be one of the best leukaemia genetics research resources in the world. Some of the most recent analyses from these data have identified new cytogenetic-based risk categories in childhood and adult acute leukaemia, which have resulted in changes in clinical practice.

I have a passion for the development of new technologies. In the 1980’s, I pioneered studies on the scanning electron microscopy of metaphase chromosomes to provide increased resolution for detailed analysis at the structural level. The demand for images from these investigations continues to this day.

From studies on deletions of the long arm of chromosome 6 (6q) in acute leukaemia, I was one of the early pioneers of chromosome mapping using fluorescence in situ hybridisation (FISH)

I was responsible for the development of FISH for the detection of chromosomal abnormalities of prognostic significance in UK acute leukaemia clinical treatment trials. FISH is now used routinely in UK and has been adopted into trial protocols in Europe and internationally. This approach led to the discovery of novel chromosomal abnormalities for which modified treatment has significantly improved survival.

Within my group we provided early development of procedures for array-based comparative genomic hybridisation (aCGH) in acute leukaemia, which now is widely used for the detection of chromosomal imbalances, not only in leukaemia but a wide range of other cancers. Using this in association with other procedures, we have identified novel chromosomal abnormalities with potential as molecular targets for therapy. My current interests involve the application of next-generation sequencing to search for novel significant mutations in acute leukaemia. Understanding of the role of genetics in the improved survival of leukaemia patients is my ultimate aim.

• Schwab C, Ryan SL, Chilton L, Elliott A, Murray J, Richardson S, Wragg C, Moppett J, Cummins M, Tunstall O, Parker CA, Saha V, Goulden N, Vora A, Moorman AV, Harrison CJ. EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications. Blood 2016, 127(18), 2214-2218.
• Ciardullo C, Willmore E, Enshaei A, Zhou P, Rand V, Soundararajan M, Hall A, Harrison C, Eswaran J. BACH2 and BCL6 Cooperatively Fuction as Tumour Suppressors in CLL. In: 21st Congress of the European Hematology Association. 2016, Copenhagen, Denmark: Ferrata Storti Foundation.
• Milani G, Durinck K, Matthijssens F, Peirs S, Pieters T, Reunes L, Lintermans B, Vandamme N, Lammens T, Li YL, Schwab C, Raimondi S, De Moerloose B, Benoit Y, Berx G, Harrison C, Basso G, Cave H, Sutton R, Asnafi V, Mullighan C, Meijerink J, Loh M, Van Vlierberghe P. Genetic characterization and therapeutic targeting of MYC translocated pediatric T-cell acute lymphoblastic leukemia. In: AACR Special Conference. 2016, Atlanta, GA, USA: American Association for Cancer Research.
• Ciardullo C, Zhou P, Willmore E, Harrison CJ, Hall A, Eswaran J, Soundararajan M. Impact of the apoptotic regulator DRAK2 in chronic lymphocytic leukemia. In: XXXVI World Congress of the International Society of Hematology. 2016, Glasgow: Wiley-Blackwell.
• Ciardullo C, Willmore E, Zhou P, Rand V, Harrison C, Hall A, Eswaran J, Soundararajan M. Impact of the apoptotic regulator DRAK2 in chronic lymphocytic leukemia. In: 21st Congress of the European Hematology Association. 2016, Copenhagen, Denmark: Fondazione Ferrata Storti.
• Irving JAE, Enshaei A, Parker CA, Sutton R, Kuiper RP, Erhorn A, Minto L, Venn NC, Law T, Yu J, Schwab C, Davies R, Matheson E, Davies A, Sonneveld E, den Boer ML, Love SB, Harrison CJ, Hoogerbrugge PM, Revesz T, Saha V, Moorman AV. Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukaemia. Blood 2016, 128(7), 911-922.
• Ryan SL, Matheson E, Grossmann V, Sinclair P, Bashton M, Schwab C, Towers W, Partington M, Elliott A, Minto L, Richardson S, Rahman T, Keavney B, Skinner R, Bown N, Haferlach T, Vandenberghe P, Haferlach C, Santibanez-Koref M, Moorman AV, Kohlmann A, Irving JA, Harrison CJ. The role of the RAS pathway in iAMP21-ALL. Leukemia 2016, 30, 1824-1831.
• Wade MA, Sunter NJ, Fordham SE, Long A, Masic D, Russell J, Harrison CJ, Rand V, Elstob C, Bown N, Rowe D, Lowe C, Cuthbert G, Bennett S, Crosier S, Bacon CM, Onel K, Scott K, Scott D, Travis LB, May FEB, Allan JM. c-MYC is a radiosensitive locus in human breast cells. Oncogene 2015, 34, 4985-4994.
• Sinclair P, Cheng J, Raninga P, Hanna R, Hollern S, Enshaei A, Blair H, Nakjang S, Ryan S, Eswaran J, Buechler L, Heidenreich O, Harrison C. A Targeted Functional Clone Tracking Assay for the Identification of Tumour Suppressor Genes in BCP- ALL Implicates the Transcription Factors FOXO3 and PRDM1. In: 57th American Society of Hematology (ASH) Annual Meeting. 2015, Orlando, FL, USA: American Society of Hematology.
• Gabriel AS, Enshaei A, Taylor J, Erhorn A, Schwab C, Rai L, Fielding A, Goulden N, Vora A, Harrison CJ, Moorman AV. Age specific incidence of partner gene and secondary abnormalities in MLL positive acute lymphoblastic leukaemia (ALL). In: 20th Congress of the European Hematology Association. 2015, Vienna, Austria: Ferrata-Storti Foundation/European Hematology Association.
• Russell LR, Jones L, Enshaei A, Rutherford J, Tonin S, Ryan S, Eswaran J, Papaemmanuil E, Tubio J, Campbell PJ, Moorman AV, Harrison C. Clincial and Genetic Landscapes Differ Between IGH-CRLF2 and P2RY8-CRLF2 Acute Lymphoblastic Leukaemia. In: 57th American Society of Hematology (ASH) Annual Meeting. 2015, Orlando, FL, USA: American Society of Hematology.
• Moorman AV, Irving J, Enshaei A, Parker CA, Sutton R, Kuiper R, Erhorn A, Minto L, Venn NC, Law T, Yu J, Schwab C, Davies R, Sonneveld E, den Boer ML, Love SB, Harrison CJ, Hoogerbrugge PM, Revesz T, Saha V. Composite Index for Risk Prediction in Relapsed Childhood Acute Lymphoblastic Leukaemia. In: 20th Congress of the European Hematology Association. 2015, Vienna: Ferrata Storti Foundation.
• Gabriel AS, Lafta FM, Schwalbe EC, Nakjang S, Cockell SJ, Iliasova A, Enshaei A, Schwab C, Rand V, Clifford SC, Kinsey SE, Mitchell CD, Vora A, Harrison CJ, Moorman AV, Strathdee G. Epigenetic landscape correlates with genetic subtype but does not predict outcome in childhood acute lymphoblastic leukemia. Epigenetics 2015, 10(8), 717-726.
• Masic D, Enshaei A, Jones L, Harrison C, Russell LJ. Genetic Characterisation of Immunoglobulin Heavy Chain Locus CCAAT Enhancer-Binding Protein Translocated Acute Lymphoblastic Leukaemia. In: 57th American Society of Hematology (ASH) Annual Meeting. 2015, Orlando, FL, USA.
• O'Connor D, Bartram J, Enshaei A, Moorman AV, Harrison C, Wade R, Clack R, Hancock J, Samarasinghe S, Moppett J, Vora AJ, Goulden N. Integration of Minimal Residual Disease with Other Patient Risk Factors Identifies a Population with Very Poor Overall Survival in Pediatric ALL: Results from the UKALL 2003 Trial. In: 57th American Society of Hematology (ASH) Annual Meeting. 2015, Orlando, FL, USA: American Society of Hematology.
• Bartram J, O'Connor D, Enshaei A, Moorman AV, Harrison C, Wade R, Clack R, Hancock J, Samarasinghe S, Moppett J, Vora AJ, Goulden N. Long Term Overall Survival of Greater Than 98% in Childhood ALL Patients with Good Risk Features and Low Risk MRD: Results from a Large Multi-Center Randomized Controlled Trial, UKALL 2003. In: 57th American Society of Hematology (ASH) Annual Meeting. 2015, Orlando, FL, USA: American Society of Hematology.
• Nicholson L, Evans C, Matheson E, Minto L, Keilty C, Sanichar M, Case M, Schwab C, Williamson D, Rainer J, Harrison C, Kofler R, Hall AG, Rednern CPF, Wheaton AD, Irving JAE. Quantitative proteomic analysis reveals maturation as a mechanism underlying glucocorticoid resistance in B lineage ALL and re-sensitization by JNK inhibition. British Journal of Haematology 2015, 171(4), 595–605.
• Lana T, de Lorenzo P, Bresolin S, Bronzini I, den Boer ML, Cave H, Fronkova E, Stanulla M, Zaliova M, Harrison CJ, de Groot H, Valsecchi MG, Biondi A, Basso G, Cazzaniga G, te Kronnie G. Refinement of IKZF1 status in pediatric Philadelphia-positive acute lymphoblastic leukemia. Leukemia 2015, 29(10), 2107-2110.
• Vicente C, Schwab C, Broux M, Geerdens E, Degryse S, Demeyer S, Lahortiga I, Elliott A, Chilton L, LaStarza R, Mecucci C, Vandenberghe P, Goulden N, Vora A, Moorman AV, Soulier J, Harrison CJ, Clappier E, Cools J. Targeted Sequencing Identifies Association Between IL7R-JAK Mutations And Epigenetic Modulators In T-Cell Acute Lymphoblastic Leukemia. Haematologica 2015, 100, 1301-1310.
• Vijayakrishnan J, Henrion M, Moorman AV, Fiege B, Kumar R, da Silva MI, Holroyd A, Koehler R, Thomsen H, Irving JA, Allan JM, Lightfoot T, Roman E, Kinsey SE, Sheridan E, Thompson PD, Hoffmann P, Nothen MM, Muhleisen TW, Eisele L, Bartram CR, Schrappe M, Greaves M, Hemminki K, Harrison CJ, Stanulla M, Houlston RS. The 9p21.3 risk of childhood acute lymphoblastic leukaemia is explained by a rare high-impact variant in CDKN2A. Scientific Reports 2015, 5, 15065.
• Eswaran J, Sinclair P, Heidenreich O, Irving J, Russell LJ, Hall A, Calado DP, Harrison CJ, Vormoor J. The pre-B-cell receptor checkpoint in acute lymphoblastic leukaemia. Leukemia 2015, 29(8), 1623-1631.
• Chilton L, Hills RK, Burnett AK, Harrison CJ. The prognostic significance of trisomy 4 in acute myeloid leukaemia is dependent on age and additional abnormalities. Leukemia 2016, 30(11), 2264–2267.
• Vijayakrishnan J, Kumar R, Henrion MYR, Moorman AV, Rachakonda PS, Hosen I, da Silva Filho MI, Holroyd A, Dobbins SE, Koehler R, Thomsen H, Irving JA, Allan JM, Lightfoot T, Roman E, Kinsey SE, Sheridan E, Thompson PD, Hoffmann P, Nöthen MM, Heilmann-Heimbach S, Jockel KH, Greaves M, Harrison CJ, Bartram CR, Schrappe M, Stanulla M, Hemminki K, Houlston RS. A genome-wide association study identifies risk loci for childhood acute lymphoblastic leukemia at 10q26.13 and 12q23.1. Leukemia 2017, 31(3), 573-579.
• Vormoor B, Veal GJ, Griffin MJ, Boddy AV, Irving J, Minto L, Case M, Banerji U, Swales KE, Tall JR, Moore AS, Toguchi M, Acton G, Dyer K, Schwab C, Harrison CJ, Grainger JD, Lancaster D, Kearns P, Hargrave D, Vormoor J. A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia. Pediatric Blood & Cancer 2017, 64(6), e26351 1-4.
• Chilton L, Harrison CJ, Ashworth I, Murdy D, Burnett AK, Grimwade D, Moorman AV, Hills RK. Clinical relevance of failed and missing cytogenetic analysis in acute myeloid leukaemia. Leukemia 2017, 31(5), 1234–1237.
• Dixon ZA, Nicholson L, Zeppetzauer M, Matheson E, Sinclair P, Harrison CJ, Irving JAE. CREBBP knockdown enhances RAS/RAF/MEK/ERK signaling in Ras pathway mutated acute lymphoblastic leukemia but does not modulate chemotherapeutic response. Haematologica 2017, 102(4), 736-745.
• Benard-Slagter A, Zondervan I, de Groot K, Ghazavi F, Sarhadi V, Van Vlierberghe P, De Moerloose B, Schwab C, Vettenranta K, Harrison CJ, Knuutila S, Schouten J, Lammens T, Savola S. Digital Multiplex Ligation-Dependent Probe Amplification for Detection of Key Copy Number Alterations in T- and B-Cell Lymphoblastic Leukemia. Journal of Molecular Diagnostics 2017, 19(5), 659-672.
• Enshaei A, OConnor D, Bartram J, Hancock J, Harrison CJ, Hough R, Samarasinghe S, Schwab C, Vora A, Wade R, Moppett J, Moorman AV, Goulden N. Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia. Journal of Clinical Oncology 2017, 36(1), 34-43.
• Schwab CJ, Nebral K, Chilton L, Leschi C, Waanders E, Boer JM, Zaliova M, Sutton R, Ofverholm II, Ohki K, Yamashita Y, Groeneveld-Krentz S, Fronkova E, Bakkus M, Tchinda J, Conceicao-Barbosa T, Fazio G, Mlynarski W, Pastorczak A, Cazzaniga G, Pombo-de-Oliveira MS, Trka J, Kirschner-Schwabe R, Imamura T, Barbany G, Stanulla M, Attarbaschi A, Panzer-Grumayer R, Kuiper RP, den-Boer ML, Cave H, Moorman AV, Harrison CJ, Strehl S. Intragenic amplification of PAX5: a novel subgroup in B-cell precursor acute lymphoblastic leukemia?. Blood Advances 2017, 1, 1473-1477.
• Laing AA, Harrison CJ, Gibson BES, Keeshan K. Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukemia. Experimental Hematology 2017, 54, 40-50.
• O'Connor D, Moorman AV, Wade R, Hancock J, Tan RMR, Bartram J, Moppett J, Schwab C, Patrick K, Harrison CJ, Hough R, Goulden N, Vora A, Samarasinghe S. Use of minimal residual disease assessment to redefine induction failure in pediatric acute lymphoblastic leukemia. Journal of Clinical Oncology 2017, 35(6), 660-667.
• Andersson A, Moorman AV, Harrison CJ, Mullighan C. Acute lymphoblastic leukaemia. In: Tosi S; Reid AG, ed. The Genetic Basis of Haematological Cancers. Chichester: Wiley Blackwell, 2016, pp.223-264.
• Russell LJ, Jones L, Enshaei A, Tonin S, Ryan SL, Eswaran J, Nakjang S, Papaemmanuil E, Tubio JM, Fielding AK, Vora A, Campbell PJ, Moorman AV, Harrison CJ. Characterisation of the genomic landscape of CRLF2-rearranged acute lymphoblastic leukemia. Genes, Chromosomes & Cancer 2016, 56(5), 363-372.
• Mughal TI, Radich JP, Deininger MW, Apperley JF, Hughes TP, Harrison CJ, Gambacorti-Passerini C, Saglio G, Cortes J, Daley GQ. Chronic Myeloid Leukemia: Reminiscences And Dreams. Haematologica 2016, 101(5), 541-558.
• Harrison CJ, Schwab C. Constitutional abnormalities of chromosome 21 predispose to iAMP21-acute lymphoblastic leukaemia. European Journal of Medical Genetics 2016, 59(3), 162-165.
• La Starza R, Barba G, Demeyer S, Pierini V, Di Giacomo D, Gianfelici V, Schwab C, Matteucci C, Vicente C, Cools J, Messina M, Crescenzi B, Chiaretti S, Foà R, Basso G, Harrison CJ, Mecucci C. Deletions of the long arm of chromosome 5 define subgroups of T-cell acute lymphoblastic leukemia. Haematologica 2016, 101(8), 951-958.
• Harrison CJ. Blood Spotlight on iAMP21 acute lymphoblastic leukemia (ALL), a high-risk pediatric disease. Blood 2015, 125(9), 1383-1386.
• Harrison CJ, Johansson B. Acute lymphoblastic leukemia. In: Cancer Cytogenetics: Chromosomal and Molecular Genetic Aberrations of Tumor Cells, Fourth Edition. Wiley Blackwell, 2015, pp.198-251.
• Johansson B, Harrison CJ. Acute myeloid leukemia. In: Cancer Cytogenetics: Chromosomal and Molecular Genetic Aberrations of Tumor Cells, Fourth Edition. Wiley Blackwell, 2015, pp.62-125.
• Harrison CJ. Advances in the Genetics of Childhood Leukaemia: a Success Story. In: 20th International Chromosome Conference. 2015, Canterbury, UK: Springer.
• Russell LJ, Jones L, Enshaei A, Rutherford J, Tonin S, Ryan S, Eswaran J, Papaemmanuil E, Tubio J, Campbell PJ, Moorman AV, Harrison C. Clincial and Genetic Landscapes Differ Between IGH-CRLF2 and P2RY8-CRLF2 Acute Lymphoblastic Leukaemia. In: 57th ASH Annual Meeting 2015. 2015, Orlando, USA: American Society of Hematology.
• Klein K, Kaspers G, Harrison CJ, Beverloo HB, Reedijk A, Bongers M, Cloos J, Pession A, Reinhardt D, Zimmerman M, Creutzig U, Dworzak M, Alonzo T, Johnston D, Hirsch B, Zapotocky M, De Moerloose B, Fynn A, Lee V, Taga T, Tawa A, Auvrignon A, Zeller B, Forestier E, Salgado C, Balwierz W, Popa A, Rubnitz J, Raimondi S, Gibson B. Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Munster Study Group. Journal of Clinical Oncology 2015, 33(36), 4247-4258.
• Masic D, Enshaei A, Jones L, Harrison C, Russell LJ. Genetic Characterisation of Immunoglobulin Heavy Chain Locus CCAAT Enhancer-Binding Protein Translocated Acute Lymphoblastic Leukaemia. In: 57th ASH Annual Meeting 2015. 2015, Orlando, USA: American Society of Hematology.
• Lopes BA, Meyer C, Barbosa TC, Poubel CP, Mansur MB, Duployez N, Bashton M, Harrison CJ, zur Stadt U, Horstmann M, Pombo-de-Oliveira MS, Palmi C, Cazzaniga G, Venn NC, Sutton R, Alonso CN, Tsaur G, Gupta SK, Bakhshi S, Marschalek R, Emerenciano M. IKZF1 Deletions with COBL Breakpoints Are Not Driven by RAG-Mediated Recombination Events in Acute Lymphoblastic Leukemia. Translational Oncology 2019, 12(5), 726-732.
• Vijayakrishnan J, Studd J, Broderick P, Kinnersley B, Holroyd A, Law PJ, Kumar R, Allan JM, Harrison CJ, Moorman AV, Vora A, Roman E, Rachakonda S, Kinsey SE, Sheridan E, Thompson PD, Irving JA, Koehler R, Hoffmann P, Nothen MM, Heilmann-Heimbach S, Jockel K-H, Easton DF, Pharaoh PDP, Dunning AM, Peto J, Canzian F, Swerdlow A, Eeles RA, Kote-Jarai Z, Muir K, Pashayan N, Henderson BE, Haiman CA, Benlloch S, Schumacher FR, Olama AAA, Berndt SI, Conti DV, Wiklund F, Chanock S, Stevens VL, Tangen CM, Batra J, Clements J, Gronberg H, Schleutker J, Albanes D, Weinstein S, Wolk A, West C, Mucci L, Cancel-Tassin G, Koutros S, Sorensen KD, Maehle L, Neal DE, Travis RC, Hamilton RJ, Ingles SA, Rosenstein B, Lu Y-J, Giles GG, Kibel AS, Vega A, Kogevinas M, Penney KL, Park JY, Stanford JL, Cybulski C, Nordestgaard BG, Brenner H, Maier C, Kim J, John EM, Teixeira MR, Neuhausen SL, De Ruyck K, Razack A, Newcomb LF, Lessel D, Kaneva R, Usmani N, Claessens F, Townsend PA, Gago-Dominguez M, Roobol MJ, Menegaux F, Greaves M, Zimmerman M, Bartram CR, Schrappe M, Stanulla M, Hemminki K, Houlston RS. Author correction: Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia. Nature Communications 2019, 10(1), 419.
• Newman AM, Zaka M, Zhou P, Erhorn A, Barnard A, Crossland RE, Wilkinson S, Wood K, Televantou D, Harrison CJ, Bomken S, Bacon CM, Rand V. Biallelic Inactivation of TP53 is Associated with an Increased Risk of Relapse in Paediatric B-Cell Non-Hodgkin Lymphoma(B-NHL). In: 50th Congress of the International Society of Paediatric Oncology (SIOP). 2019, Kyoto, Japan: John Wiley & Sons, Inc.
• Milani G, Matthijssens F, Van Loocke W, Durinck K, Roels J, Peirs S, Thenoz M, Pieters T, Reunes L, Lintermans B, Vandamme N, Lammens T, Van Roy N, Van Nieuwerburgh F, Deforce D, Schwab C, Raimondi S, Dalla Pozza L, Carroll AJ, De Moerloose B, Benoit Y, Goossens S, Berx G, Harrison CJ, Basso G, Cave H, Sutton R, Asnafi V, Meijerink J, Mullighan C, Loh M, Van Vlierberghe P. Genetic characterization and therapeutic targeting of MYC-rearranged T cell acute lymphoblastic leukaemia. British Journal of Haematology 2019, 185(1), 169-174.
• Sinclair PB, Ryan S, Bashton M, Hollern S, Hanna R, Case M, Schwalbe EC, Schwab CJ, Cranston RE, Young BD, Irving JAE, Vora AJ, Moorman AV, Harrison CJ. SH2B3 inactivation through CN-LOH-12q is uniquely associated with B-cell precursor ALL with iAMP21 or other chromosome 21 gain. Leukemia 2019, 33, 1881-1894.
• Hamadeh L, Enshaei A, Schwab C, Alonso CN, Attarbaschi A, Barbany G, den Boer ML, Boer JM, Braun M, Dalla Pozza L, Elitzur S, Emerenciano M, Fechina L, Felice MS, Fronkova E, Haltrich I, Heyman MM, Horibe K, Imamura T, Jeison M, Kovács G, Kuiper RP, Mlynarski W, Nebral K, Ivanov Öfverholm I, Pastorczak A, Pieters R, Piko H, Pombo-de-Oliveira MS, Rubio P, Strehl S, Stary J, Sutton R, Trka J, Tsaur G, Venn N, Vora A, Yano M, Harrison CJ, Moorman AV. Validation of the United Kingdom copy-number alteration classifier in 3239 children with B-cell precursor ALL. Blood Advances 2019, 3(2), 148-157.
• Newman AM, Zaka M, Zhou P, Erhorn A, Crossland RE, Wilkinson S, Enshaei A, Taj M, Wood K, Televantou D, Turner SD, Burke A, Harrison CJ, Bomken S, Bacon CM, Rand V. Biallelic inactivation of TP53 is associated with an increased risk of relapse in paediatric B-cell non-Hodgkin lymphoma (B-NHL). In: Sixth International Symposium on Childhood, Adolescent and Young Adult Non‐Hodgkin Lymphoma. 2018, Rotterdam, Netherlands: British Journal of Haematology.
• Sinclair PB, Blair HH, Ryan SL, Buechler L, Cheng J, Clayton J, Hanna R, Hollern S, Hawking Z, Bashton M, Schwab CJ, Jones L, Russell LJ, Marr H, Carey P, Halsey C, Heidenreich O, Moorman AV, Harrison CJ. Dynamic clonal progression in xenografts of acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21. Haematologica 2018, 103, 634-644.
• Vijayakrishnan J, Studd J, Broderick P, Kinnersley B, Holroyd A, Law PJ, Kumar R, Allan JM, Harrison CJ, Moorman AV, Vora A, Roman E, Rachakonda S, Kinsey SE, Sheridan E, Thompson PD, Irving JA, Koehler R, Hoffmann P, Nothen MM, Heilmann-Heimbach S, Jockel K-H, Easton DF, Pharaoh PDP, Dunning AM, Peto J, Canzian F, Swerdlow A, Eeles RA, Kote-Jarai Z, Muir K, Pashayan N, Greaves M, Zimmerman M, Bartram CR, Schrappe M, Stanulla M, Hemminki K, Houlston RS, Henderson BE, Haiman CA, Benlloch S, Schumacher FR, Olama AAA, Berndt SI, Conti DV, Wiklund F, Chanock S, Stevens VL, Tangen CM, Batra J, Clements J, Gronberg H, Schleutker J, Albanes D, Weinstein S, Wolk A, West C, Mucci L, Cancel-Tassin G, Koutros S, Sorensen KD, Maehle L, Neal DE, Travis RC, Hamilton RJ, Ingles SA, Rosenstein B, Lu Y-J, Giles GG, Kibel AS, Vega A, Kogevinas M, Penney KL, Park JY, Stanford JL, Cybulski C, Nordestgaard BG, Brenner H, Maier C, Kim J, John EM, Teixeira MR, Neuhausen SL, De Ruyck K, Razack A, Newcomb LF, Lessel D, Kaneva R, Usmani N, Claessens F, Townsend PA, Dominguez MG, Roobol MJ, Menegaux F. Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia. Nature Communications 2018, 9(1), 1340.
• Newman AM, Zhou P, Zaka M, Harrison CJ, Bomken S, Bacon CM, Rand V. Genomic landscape of adult and paediatric B-cell Non-Hodgkin lymphoma. In: Sixth International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma. 2018, Rotterdam, Netherlands: British Journal of Haematology.
• Degryse S, Bornschein S, De Bock CE, Leroy E, Bempt MV, Demeyer S, Jacobs K, Geerdens E, Gielen O, Soulier J, Harrison CJ, Constantinescu SN, Cools J. Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL. Blood 2018, 131(4), 421-425.
• Potter N, Jones L, Blair H, Strehl S, Harrison CJ, Greaves M, Kearney L, Russell LJ. Single cell analysis identifies CRLF2 rearrangements as both early and late events in Down syndrome and non-Down syndrome acute lymphoblastic leukaemia. Leukemia 2019, 33, 893-904.
• Kampen KR, Sulima SO, Verbelen B, Girardi T, Vereecke S, Rinaldi G, Verbeeck J, Op de Beeck J, Uyttebroeck A, Meijerink JPP, Moorman AV, Harrison CJ, Spincemaille P, Cools J, Cassiman D, Fendt S-M, Vermeersch P, de Keersmaecker K. The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALL. Leukemia 2018, 33(2), 319-322.
• Furness CL, Mansur MB, Weston VJ, Ermini L, van Delft FW, Jenkinson S, Gale R, Harrison CJ, Pombo-de-Oliveira MS, Sanchez-Martin M, Ferrando AA, Kearns P, Titley I, Ford AM, Potter NE, Greaves M. The subclonal complexity of STIL-TAL1+ T-cell acute lymphoblastic leukaemia. Leukemia 2018, 32, 1984-1993.
• Girardi T, Vereecke S, Sulima SO, Khan Y, Fancello L, Briggs JW, Schwab C, De Beeck JO, Verbeeck J, Royaert J, Geerdens E, Vicente C, Bornschein S, Harrison CJ, Meijerink JP, Cools J, Dinman JD, Kampen KR, De Keersmaecker K. The T-cell leukemia-associated ribosomal RPL10 R98S mutation enhances JAK-STAT signaling. Leukemia 2018, 32(3), 809-819.
• Li Y, Schwab C, Ryan SL, Papaemmanuil E, Robinson HM, Jacobs P, Moorman AV, Dyer S, Borrow J, Griffiths M, Heerema NA, Carroll AJ, Talley P, Bown N, Telford N, Ross FM, Gaunt L, McNally RJ, Young BD, Sinclair P, Rand V, Teixeira MR, Joseph O, Robinson B, Maddison M, Dastugue N, Vandenberghe P, Haferlach C, Stephens PJ, Cheng J, Van-Loo P, Stratton MR, Campbell PJ, Harrison CJ. Constitutional and somatic rearrangement of chromosome 21 in acute lymphoblastic leukaemia. Nature 2014, 508(7494), 98-102.
• Li Y, Schwab C, Ryan S, Papaemmanuil E, Robinson HM, Jacobs P, Van Loo P, Stratton MR, Campbell PJ, Harrison CJ. Constitutional and somatic rearrangement of chromosome 21 in acute lymphoblastic leukaemia. In: 23rd Biennial Congress of the European Association for Cancer Research. 2014, Munich, Germany: Pergamon Press.
• Harrison CJ, Johansson B. Acute Lymphoblastic Leukaemia. In: Heim, S.; Mitelman, F. F. Mitelman, ed. Cancer Cytogenetics. New Jersey, USA: John Wiley & Sons Inc, 2009, pp.233-296.
• Parker H, Parker H, Cheung KL, Cheung KL, Robinson HM, Robinson HM, Harrison CJ, Harrison CJ, Strefford JC, Strefford JC. Cytogenetic and genomic characterization of cell line ARH77. Cancer Genet Cytogenet 2008, 181(1), 40-5.
• Ross FM, Harrison CJ. Karyotyping lymph node biopsies in non-Hodgkin's lymphoma. In: Illidge, T.; Johnson, P.W.M, ed. Lymphoma: methods and protocols. New Jersey, USA: Humana Press Inc, 2005, pp.93-107.
• Chessells JM, Harrison CJ, Kempski H, Webb DK, Wheatley K, Hann IM, Stevens RF, Harrison G, Gibson BE. Clinical features, cytogenetics and outcome in acute lymphoblastic and myeloid leukaemia of infancy: report from the MRC Childhood Leukaemia working party. Leukemia 2002, 16(5), 776-784.
• Hann I, Vora A, Harrison G, Harrison C, Eden O, Hill F, Gibson B, Richards S. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol. British Journal of Haematology 2001, 113(1), 103-114.
• Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, Wheatley K, Burnett AK, Goldstone AH. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001, 98(5), 1312-1320.
• Harrison CJ. The lymphomas and chronic lymphoproliferative disorders. In: Rooney, DE, ed. Human cytogenetics: malignancy and acquired abnormalities, a practical approach. Oxford: Oxford University Press, 2000, pp.87-109.
• Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 1998, 92(7), 2322-2333.
• Rack K, Harrison CJ, Macintyre E. Apport des techniques d'hybridation flourescente in situ dans les hemopthies malignes. In: Encyclopedie Medico-Chirurgicale. Paris: Elsevier, 1997.